Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03059069 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

The Effect of Gliatamin (Chonline Alphoscerate) on Depressive Mood in Type 2 Diabetes Patients

StatusRecruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗
Record status
This record was last updated February 24, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.

Record History

See every version on ClinicalTrials.gov ↗

  1. Primary and study completion dates: Jun 30, 2019 to Jun 30, 2025
    • Secondary endpoints: 1 to 12
    v4
  2. Re-verified, no change to tracked fieldsv3
  3. Primary and study completion dates: Jun 30, 2018 to Jun 30, 2019
    • Site details revised
    v2
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
Yonsei University
239 trials monitored
See 2 trials at risk
Diabetes
5,087 trials monitored
See 222 trials at risk
Depression
3,055 trials monitored
See 173 trials at risk
Type 2 Diabetes
2,231 trials monitored
See 111 trials at risk
The aim of this study is to investigate the effect of Gliatamin (chonline alphoscerate) on depressive mood in type 2 diabetes patients and demonstrate the impact of improved depressive mood could be influence the patient's quality of life and glycemic control.
Trial Details
NCT Number NCT03059069
Lead Sponsor Yonsei University
Conditions
(from sponsor)		 Type2 Diabetes With Depressive Mood
Enrollment 60 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov